Physician profile
Eric D Reines
NPI 1700889342
$4,854.86
in general payments reported to CMS, 2019-2025
38 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $849 · 2021: $1,349 · 2022: $613 · 2023: $506 · 2024: $362 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.40 |
| Education | $182.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $781.36 | 2019-2024 | Jardiance, Baqsimi, Lyumjev |
| Corcept Therapeutics | $587.60 | 2019-2024 | Korlym |
| Abbvie INC. | $396.54 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $343.89 | 2019-2023 | Steglatro, Verquvo, Belsomra |
| Gilead Sciences, INC. | $328.36 | 2019-2023 | |
| Novo Nordisk INC | $273.55 | 2019-2024 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $264.58 | 2020-2024 | Recorlev |
| Viiv Healthcare Company | $259.67 | 2019-2021 | |
| Shionogi INC | $182.16 | 2025 | Fetroja |
| Amneal Pharmaceuticals LLC | $174.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $103.11 | 2019-2024 | |
| Mannkind Corporation | $102.13 | 2020-2022 | |
| Abbott Laboratories | $99.23 | 2021-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $88.82 | 2021-2023 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $80.25 | 2019-2023 | Farxiga |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $75.45 | 2019-2021 | |
| Janssen Products, LP | $72.00 | 2019 | |
| Recordati_rare_diseases_inc. | $71.13 | 2021-2024 | Signifor Lar, Isturisa |
| Ibsa Pharma INC. | $70.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.69 | 2020-2021 | |
| Insulet Corporation | $51.92 | 2021-2022 | |
| Lifescan, INC. | $47.38 | 2019-2021 | |
| Tolmar, INC. | $47.31 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.13 | 2021 | |
| Clarus Therapeutics INC. | $29.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.54 | 2022 | |
| Theratechnologies INC. | $23.84 | 2019 | |
| Janssen Biotech, INC. | $21.98 | 2019 | |
| Acella Pharmaceuticals, LLC | $21.79 | 2024 | NP Thyroid 60 |
| Azurity Pharmaceuticals, INC. | $20.49 | 2023 | Adthyza |
| Acerus Pharmaceuticals Corporation | $19.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.26 | 2019 | |
| Radius Health, INC. | $16.58 | 2023 | Tymlos |
| Allergan, INC. | $16.35 | 2019 | |
| Pfizer INC. | $15.30 | 2021 | |
| Astellas Pharma US INC | $14.27 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $13.01 | 2021 | |
| Tandem Diabetes Care, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Reines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.